Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Colorectal cancer (CRC) typically shows limited response to immune-checkpoint inhibitors targeting Programmed cell death protein 1 (PD1)/programed death ligand 1 (PDL1).
• A specific subtype of CRC, defined by mismatch repair deficiency or microsatellite instability-high (MSI-high) status, exhibits significant sensitivity to PD1-targeted therapies.
• MSI-high CRC is recognized as a distinct molecular and immunological entity within colorectal cancer.

Purpose of the Study:

• To review the current biological understanding of MSI-high colorectal cancer.
• To outline ongoing and completed clinical trials evaluating immunotherapy in MSI-high CRC.
• To highlight the importance of the tumor immune microenvironment in predicting treatment response.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of molecular and immunological characteristics of MSI-high CRC.
• Summary of clinical trial data for PD1/PDL1 inhibitors in CRC.

Main Results:

• Unselected CRC cohorts demonstrate minimal benefit from PD1/PDL1 blockade.
• MSI-high CRC exhibits substantial antitumor activity when treated with PD1 inhibitors.
• The immunological microenvironment of MSI-high tumors is crucial for therapeutic efficacy.

Conclusions:

• MSI-high CRC represents a unique subset responsive to immunotherapy.
• Further research into the tumor immune microenvironment is essential for optimizing immune-based strategies.
• Targeting PD1 in MSI-high CRC holds significant therapeutic potential.